

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Durvalumab for maintenance treatment of unresectable non-small cell lung cancer after platinum- based chemoradiation

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal document

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

There were no equalities issues identified during the scoping process.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

<p>The statement from the Cancer Drugs Fund clinical lead raised an equalities consideration about access to durvalumab for patients who have insufficient tissue for PD-L1 testing or whose PD-L1 test fails. The statement highlighted that it is NHS England's intention for all patients to have PD-L1 testing but occasionally the availability of results can defy commissioning intention.</p>

<p>The committee considered this equalities consideration but concluded that it was not a relevant equalities issue. This is because NICE can only appraise technologies within their marketing authorisation, and a recommendation for people who have insufficient tissue for PD-L1 testing or whose PD-L1 test fails would be outside the marketing authorisation.</p>

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No other equalities issues were raised.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The committee did not consider that the recommendations make it more difficult for a specific group to access durvalumab (within its intended marketing authorisation).

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

NA

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The committee did not consider that there were any equalities issues relevant to the appraisal. This is reflected in the FAD (Section 3.12).

Approved by Associate Director (name): ...Linda Landells.....

Date: 25 February 2019